v3.26.1
REVENUES
 3 Months Ended
Mar. 31, 2026
Revenue from Contract with Customer [Abstract]  
REVENUES REVENUES
Disaggregation of Revenues
The following table summarizes our Total revenues:
Three Months Ended March 31, 2026Three Months Ended March 31, 2025
(in millions)U.S.EuropeRest of WorldTotalU.S.EuropeRest of WorldTotal
Product sales:
HIV
Biktarvy$2,573 $437 $352 $3,361 $2,474 $375 $301 $3,150 
Descovy761 23 23 807 538 21 27 586 
Genvoya215 33 16 264 305 40 19 364 
Odefsey153 59 9 221 215 57 10 281 
Symtuza - Revenue share(1)
107 28 3 138 82 29 3 114 
Yeztugo158 — 7 166 — — — — 
Other HIV(2)
36 27 9 73 50 31 10 91 
Total HIV4,004 607 419 5,030 3,664 553 370 4,587 
Liver Disease
Livdelzi115 18 — 133 40 — — 40 
Sofosbuvir/Velpatasvir(3)
141 60 82 283 166 80 99 346 
Vemlidy91 13 132 237 100 12 140 252 
Other Liver Disease(4)
15 78 21 114 28 76 17 121 
Total Liver Disease362 170 235 767 335 168 256 758 
Veklury112 14 18 144 199 22 82 302 
Oncology
Cell Therapy
Tecartus30 37 8 75 40 31 8 78 
Yescarta120 146 67 332 160 149 77 386 
Total Cell Therapy150 183 74 407 200 180 84 464 
Trodelvy253 95 54 402 181 75 37 293 
Total Oncology403 278 129 810 381 255 121 757 
Other
AmBisome7 59 72 138 5 67 66 139 
Other(5)
39 8 11 58 47 9 14 70 
Total Other46 67 83 196 52 76 81 209 
Total product sales4,926 1,137 883 6,946 4,631 1,073 909 6,613 
Royalty, contract and other revenues— 8 6 14 37 11 6 54 
Total revenues$4,926 $1,144 $889 $6,960 $4,668 $1,084 $915 $6,667 
_______________________________
(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen Ireland”).
(2)    Includes Atripla, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.
(3)    Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4)    Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Hepsera, Sovaldi, Viread and Vosevi.
(5)    Includes Cayston, Jyseleca, Letairis and Zydelig.
Revenues Recognized from Performance Obligations Satisfied in Prior Years
The following table summarizes revenues recognized from performance obligations satisfied in prior years:
Three Months Ended
March 31,
(in millions)20262025
Revenue share with Janssen Ireland and royalties for licenses of intellectual property$152 $157 
Changes in estimates$232 $214 
Contract Balances
The following table summarizes our contract balances:
(in millions)March 31, 2026December 31, 2025
Contract assets$589 $629 
Contract liabilities(1)
$47 $48 
_______________________________
(1)    Future revenues recognized from contract liabilities are not expected to be material in any one year.